Acurion, Inc. — SEC Form D Filing
Acurion, Inc. filed an SEC Form D on April 15, 2026, reporting $4.14M raised in Health Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 15, 2026
- Amount reported
- $4.14M
- Round stage
- Seed
- Industry
- Health Technology
- Website
- https://acurionhealth.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Many cancer patients do not receive approved precision oncology therapies in time due to delays in testing.
Solution
Acurion's OncoGaze™ technology provides genomic insights quickly, enabling oncologists to offer precision therapies sooner.
Why now
The increasing number of FDA-approved precision oncology therapies highlights the need for faster testing and treatment delivery.
Verdict
Investors were drawn to Acurion because the urgency of delivering precision oncology therapies faster resonated in the context of the expanding market for such treatments, not because they had clear evidence of significant differentiation from incumbents. The implicit bet was that the demand for quick genomic insights would sustain Acurion's growth trajectory. However, the limited upside lies in the competitive landscape, where established players may easily overshadow new entrants unless Acurion demonstrates a distinct technological edge.
Source: SEC EDGAR Form D filing